Lyell Immunopharma, Inc. (LYEL) Operating cash flow 2019–2025
Lyell Immunopharma, Inc. (LYEL) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$150.0MFY2025 · since FY2019: $39.5M → -$150.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$150.0M | +7.6% |
| FY2024 | -$162.4M | +0.8% |
| FY2023 | -$163.7M | +3.5% |
| FY2022 | -$169.6M | -34.3% |
| FY2021 | -$126.2M | +21.5% |
| FY2020 | -$160.9M | -507.5% |
| FY2019 | $39.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Net marginLYEL Gross profitLYEL Gross marginLYEL Operating incomeLYEL Operating marginLYEL Free cash flowLYEL Capital expendituresLYEL Return on equityLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Total liabilitiesLYEL Shareholders’ equityLYEL overview →